Please assess the completion status of the following clinical trial:

Trial Title: Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of prostate cancer~* Prostate specific antigen (PSA) greater than or equal to 5 ng/mL~* Recent completion of first hormone treatment \[intermittent androgen deprivation with a Luteinising hormone releasing hormone (LHRH) analogue\]~* Screening PSA ≤1.0 ng/mL (within 6 weeks prior to study Day1)~Exclusion Criteria:~* Bone or soft tissue metastases~* Significant cardiovascular disease including hypertension not controlled by medical therapy or history of irregular heart beats or recent heart attack

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vandetanib (Type: EXPERIMENTAL): 300 mg orally, once daily for up to 18 months
- Placebo (Type: PLACEBO_COMPARATOR): orally, once daily for up to 18 months

Based on this trial design, predict the completion outcome and termination type (if applicable).